<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03987204</url>
  </required_header>
  <id_info>
    <org_study_id>2000022064</org_study_id>
    <nct_id>NCT03987204</nct_id>
  </id_info>
  <brief_title>Ivabradine for Rate Control in Permanent Atrial Fibrillation</brief_title>
  <official_title>Ivabradine for Rate Control in Permanent Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ivabradine may be useful as a rate controlling agent in atrial fibrillation without negative&#xD;
      effects on hemodynamics and inotropy. The objective in this proof of concept study is to&#xD;
      investigate the hypothesis that ivabradine will slow the ventricular response in patients&#xD;
      with permanent atrial fibrillation and previously-implanted pacemakers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a simple cross-over study, the investigators will evaluate the impact of oral Ivabradine&#xD;
      on exercise treadmill test, percent pacing as stored in pacemaker diagnostics, and 6 minute&#xD;
      walk test.&#xD;
&#xD;
      Aim/Hypotheses&#xD;
&#xD;
      â€¢ To determine if the addition of Ivabradine to baseline cardiac medications slows mean and&#xD;
      maximum heart rates in permanent atrial fibrillation&#xD;
&#xD;
        -  Ivabradine will lower mean and maximum heart rates on treadmill exercise test, without&#xD;
           lowering blood pressure&#xD;
&#xD;
        -  Ivabradine will increase percent pacing, and lower rates over time as shown on pacemaker&#xD;
           diagnostic data&#xD;
&#xD;
        -  Ivabradine will improve exertional symptoms and exercise tolerance due to atrial&#xD;
           fibrillation as measured by the Borg's scale during a six-minute walk test.&#xD;
&#xD;
      Study Design&#xD;
&#xD;
        1. Patients with permanent atrial fibrillation will undergo baseline exercise treadmill&#xD;
           test, measurement of heart rates and percent pacing from pacemaker diagnostics, and a 6&#xD;
           minute walk test with symptomatic assessment of dyspnea using the Borg's scale score.&#xD;
&#xD;
        2. Oral Ivabradine will be started at 5 mg twice daily, and up-titrated to a maximum dose&#xD;
           of 7.5 mg twice daily at 7 days if percent pacing has not increased significantly or&#xD;
           rates have not slowed more than 20bpm.&#xD;
&#xD;
        3. Exercise treadmill test, measurement of heart rates and percent pacing from pacemaker&#xD;
           diagnostics, and a 6 minute walk test with symptomatic assessment of dyspnea using the&#xD;
           Borg's scale score will be repeated at 2 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2019</start_date>
  <completion_date type="Actual">September 17, 2019</completion_date>
  <primary_completion_date type="Actual">September 17, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Heart Rate in Daily Life</measure>
    <time_frame>2 weeks</time_frame>
    <description>Average ventricular heart rate derived using pacemaker interrogation over 2 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Pacing in Daily Life</measure>
    <time_frame>2 weeks</time_frame>
    <description>Average percent pacing derived using pacemaker interrogation over 2 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate on Treadmill</measure>
    <time_frame>2 weeks</time_frame>
    <description>Average ventricular heart rate will be recorded after the patient exercises on a treadmill using a heart rate monitor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptoms and Exercise Tolerance</measure>
    <time_frame>2 weeks</time_frame>
    <description>Patients will undergo a 6 minute walk test, and symptoms and distance walked as measured by standard 6 minute walk protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>2 weeks</time_frame>
    <description>Blood pressures will be monitored using a blood pressure cuff with the patient at rest for 10 minutes</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Atrial Fibrillation, Persistent</condition>
  <arm_group>
    <arm_group_label>Ivabradine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with permanent atrial fibrillation and previously implanted pacemakers who will be started on ivabradine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivabradine</intervention_name>
    <description>Ivabradine will be started and titrated to heart rate slowing of 20 bpm or greater, or an increase in pacing.</description>
    <arm_group_label>Ivabradine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with stable blood pressures with permanent atrial fibrillation and implanted&#xD;
             pacemaker pacing less than 50% of the time, with or without concomitant beta blocker&#xD;
             or calcium channel blocker use&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with uncontrolled hypertension will be excluded&#xD;
&#xD;
          -  To eliminate confounding effects, patients on Digoxin therapy will be excluded&#xD;
&#xD;
          -  Patients on anti-arrhythmic therapy&#xD;
&#xD;
          -  Patients with pre-excitation on EKG&#xD;
&#xD;
          -  Patients who pace &gt; 50% of the time&#xD;
&#xD;
          -  Patients with severe Child-Pugh C hepatic impairment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rachel Lampert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hyon Jae Lee, MD</last_name>
    <role>Study Director</role>
    <affiliation>Yale New Haven Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>June 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2019</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

